Teva is looking to fill any gap when it comes to the new biologics for chronic migraine with the company confirming TGA approval of AJOVY (fremanezumab) ahead of this week's PBAC meeting. …
Latest Video
New Stories
-
PHARMAC switch now blamed for three deaths
November 14, 2019 - - Latest News -
7CPA deal unlikely in 2019
November 14, 2019 - - Latest News -
New report highlights system challenge for Alzheimer's treatment
November 14, 2019 - - Latest News -
Official opening of new Merck headquarters
November 13, 2019 - - Latest News -
AusBiotech releases update on local regenerative medicine sector
November 13, 2019 - - Latest News -
Department confirms emergency supply arrangements for bushfire areas
November 13, 2019 - - Latest News -
Mark Glover: The tech opportunity for clinical trials
November 13, 2019 - - Latest News